XL-protein GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:XL-protein GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11227
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XL-protein GmbH (XL-protein) is a biopharmaceutical company that develops second generation biopharmaceutical drugs. The company develops PASylation technology, designed to enable the biopharmaceuticals drug development with extended plasma half-life and enhanced action. It provides its technology for partners at preclinical stage to find out the areas of usage of their products for treating several injuries and to uncover the efficiency. The company offers PASylated proteins for infectious diseases, inflammation, oncology, metabolic diseases, obesity, diabetes and multiple sclerosis. It provides therapeutic proteins such as growth factors, hormones, and cytokines. XL-protein is headquartered in Freising, Germany.

XL-protein GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XL-protein GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
XL-protein GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Horizon Pharma Enters into Agreement with XL-protein 10
AdAlta Enters into Agreement with XL-protein 11
DNX Biopharma Enters into Joint Development Partnership with XL-protein 12
XL-protein Enters into Collaboration Agreement with Yeda Research 13
Wacker Biotech and XL-protein Enter into Agreement 14
Licensing Agreements 15
Jazz Pharma Enters into License Agreement with XL-protein 15
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 16
Easton Pharma Enters into Licensing Agreement with XL-protein 17
XL-protein Enters Into Licensing Agreement With IBC Generium For PASylated Therapeutics 18
XL-protein GmbH – Key Competitors 19
XL-protein GmbH – Key Employees 20
XL-protein GmbH – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
XL-protein GmbH, Pharmaceuticals & Healthcare, Key Facts 2
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XL-protein GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XL-protein GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Horizon Pharma Enters into Agreement with XL-protein 10
AdAlta Enters into Agreement with XL-protein 11
DNX Biopharma Enters into Joint Development Partnership with XL-protein 12
XL-protein Enters into Collaboration Agreement with Yeda Research 13
Wacker Biotech and XL-protein Enter into Agreement 14
Jazz Pharma Enters into License Agreement with XL-protein 15
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 16
Easton Pharma Enters into Licensing Agreement with XL-protein 17
XL-protein Enters Into Licensing Agreement With IBC Generium For PASylated Therapeutics 18
XL-protein GmbH, Key Competitors 19
XL-protein GmbH, Key Employees 20

List of Figures
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
XL-protein GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[XL-protein GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Health Dialog Services Corp:企業の戦略的SWOT分析
    Health Dialog Services Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Polyplus-Transfection SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Polyplus-Transfection SA (Polyplus) is a biotechnology company that develops and markets solutions for in vivo and in vitro delivery of nucleic acids in research, bioproduction and therapeutics. The company develops RNA interference such as STICKY SIRNA and SIRNAPLUS for in vivo research. It …
  • Eurocommercial Properties NV:企業の戦略・SWOT・財務分析
    Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report Summary Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • University of Texas MD Anderson Cancer Center:医療機器:M&Aディール及び事業提携情報
    Summary University of Texas MD Anderson Cancer Center (MD Anderson) is one of the leading cancer care centers in the US. It is one of the three original comprehensive cancer care centers designated by the National Cancer Act of 1971 in the US and is affiliated to University of Texas Health. MD Ander …
  • KPMG International Coop:企業の戦略的SWOT分析
    KPMG International Coop - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • CEWE Stiftung & Co.KGaA (CWC):企業の財務・戦略的SWOT分析
    CEWE Stiftung & Co.KGaA (CWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Genesis HealthCare Corp (GEN)-製薬・医療分野:企業M&A・提携分析
    Summary Genesis HealthCare Corp (Genesis HealthCare) is a healthcare company that provides nursing and rehabilitation therapy. The company offers services such as rehabilitation therapy, ventilator care, dialysis care, private duty home care, hospice care, respiratory health, post acute management a …
  • iBio Inc (IBIO):企業の財務・戦略的SWOT分析
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析
    Summary Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent he …
  • Takara Bio Inc (4974):製薬・医療:M&Aディール及び事業提携情報
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • New World Development Co Ltd (17):企業の財務・戦略的SWOT分析
    New World Development Co Ltd (17) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • PICC Property and Casualty Co Ltd:企業の戦略・SWOT・財務情報
    PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report Summary PICC Property and Casualty Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Korea Development Bank:企業の戦略・SWOT・財務情報
    Korea Development Bank - Strategy, SWOT and Corporate Finance Report Summary Korea Development Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Isofol Medical AB (ISOFOL)-製薬・医療分野:企業M&A・提携分析
    Summary Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company developing folate-based therapies for the treatment of cancer patients. The company’s clinical lead candidate Modufolin, a metabolite is under clinical phase I/II development being evaluated for the treatment of colorectal …
  • Unum Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Unum Therapeutics Inc (Unum) is a cancer cell therapy company that discovers, develops, and commercializes novel antibody-coupled cellular immunotherapies. The company uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology for discovering and developing new cellular immunoth …
  • Dentsu, Inc.:企業の戦略・SWOT・財務情報
    Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Chubu Electric Power Company, Incorporated:企業の戦略・SWOT・財務分析
    Chubu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Chubu Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Hyundai Steel Co:戦略・SWOT・企業財務分析
    Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Steel Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Power Mech Projects Ltd (POWERMECH):企業の財務・戦略的SWOT分析
    Power Mech Projects Ltd (POWERMECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆